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atients With Implantable Cardioverter-Defibrillators
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OBJECTIVES This study compared cardiac resynchronization therapy’s (CRT) impact on ventricular
tachyarrhythmia susceptibility in patients who, due to worsening heart failure (HF)
symptoms, underwent a replacement of a conventional implantable cardioverter-defibrillator
(ICD) with a CRT-ICD.
BACKGROUND Cardiac resynchronization therapy is an effective addition to conventional treatment of HF in
many patients with left ventricular systolic dysfunction. However, whether CRT-induced
improvements in HF status also reduce susceptibility to life-threatening arrhythmias is less
certain.
METHODS Clinical and ICD electrogram data were evaluated in 18 consecutive ICD patients who
underwent an upgrade to CRT-ICD. Pharmacologic HF therapy was not altered during
follow-up. The definition of ventricular tachycardia (VT) and ventricular fibrillation (VF) for
each patient was as determined by device programming. Statistical comparisons used paired
t tests.
RESULTS Findings were recorded during two time periods: 47  21 months (range 24 to 70 months)
before and 14  2 months (range 9 to 18 months) after CRT upgrade. At time of upgrade,
patient age was 69  11 years and ejection fraction was 21  8%. Before CRT the frequency
of VT, VF, and appropriate ICD shocks was 0.31 1.23, 0.047 0.083, and 0.048 0.085
episodes/month/patient, respectively. After CRT-ICD, VT and VF arrhythmia burdens and
frequency of shocks were respectively 0.13  0.56, 0.001  0.004, and 0.003  0.016
episodes/month/patient (p  0.59, 0.03, and 0.05 vs. pre-CRT).
CONCLUSIONS Arrhythmia frequency and number of appropriate ICD treatments were reduced after upgrade
to CRT-ICD for HF treatment. Thus, apart from hemodynamic benefits, CRT may also
ameliorate ventricular tachyarrhythmia susceptibility in HF patients. (J Am Coll Cardiol
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.04.0672005;46:2258–63) © 2005 by the American College of Cardiology Foundation
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(iventricular stimulation (i.e., cardiac resynchronization
herapy [CRT]) has been shown to improve cardiac func-
ion, diminish heart failure (HF) hospitalization frequency,
nd enhance quality of life for many patients with severe left
entricular systolic dysfunction and intraventricular conduc-
ion disease who are already being administered maximally
olerated pharmacological treatment for HF (1–11). How-
ver, whether CRT benefits extend to diminished suscepti-
ility to potentially life-threatening arrhythmias remains
ontroversial (8–15). This study was designed to further
ddress the potential for CRT to provide an antiarrhythmia
From the *Cardiac Arrhythmia Center, University of Minnesota Medical School,
inneapolis, Minnesota; and the †Central Minnesota Heart Center, St. Cloud
ospital, St. Cloud, Minnesota. This work was supported by a grant from the Cardiac
rrhythmia Center at the University of Minnesota, Minneapolis, Minnesota. Dr.
rmis was supported in part by the Midwest Arrhythmia Research Foundation,
dina, Minnesota. Dr. Benditt is a consultant and shareholder for Medtronic Inc.,
nd St. Jude Medical Inc. Dr. Lurie is a consultant and shareholder for St. Jude
edical Inc.i
Manuscript received March 13, 2005; revised manuscript received April 2, 2005,
ccepted April 13, 2005.enefit. To this end, we compared the impact of biventricu-
ar stimulation on the frequency and characteristics of doc-
mented ventricular tachyarrhythmias in patients who, for
urposes of ameliorating HF symptoms, underwent an “up-
rade” of a conventional implantable cardioverter-
efibrillator (ICD) system to a CRT-ICD system. Thus,
ach patient included in this study served as his/her own
ontrol.
ETHODS
atient population. The study population comprised a
onsecutive series of 18 patients who underwent successful
pgrade from conventional ICD therapy to a biventricular
CD (CRT-ICD) at either the University of Minnesota,
inneapolis, Minnesota, or Central Minnesota Heart Cen-
er, St. Cloud, Minnesota. Upgrade to CRT was based
olely on conventionally accepted HF indications at the time
i.e., increased pulmonary and/or peripheral edema, increas-
ng exertional intolerance), with enrollment concluding in
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he frequency and nature of documented ventricular ar-
hythmias, only those individuals with a minimum eight
onths after CRT follow-up were included. Arrhythmia
requency and characteristics before upgrade were determined
y retrospective assessment of ICD follow-up records. After
RT, all arrhythmia features were assessed prospectively. In
egard to hemodynamic effects of CRT upgrade, left ven-
ricular ejection fraction (LVEF) was reassessed at approx-
mately three to six months. Improvement of 5% to 10% was
bserved in 13 patients, and no detectable change occurred
n the remainder. Two deaths occurred at 8 months after
RT-ICD; otherwise none of the patients was lost to
ollow-up. Data review procedures were approved in accor-
ance with institutional guidelines.
Demographic features, LVEF, pharmacological treatment,
nd HF functional class (New York Heart Association
NYHA]) are summarized in Table 1. The primary end
oint during follow-up was ventricular tachyarrhythmia
urden (see definitions in the following text).
mplantation technique. Left ventricular stimulation was
chieved in most cases by placement of a permanent pacing
ead in the coronary sinus using a pre-formed introducer
echnique (16–18), and advancing it to a venous tributary
erving the mid-left ventricular free wall. In a minority of
nstances, conventional over-the-wire introduction systems
ere utilized. In all cases, devices were programmed with
2-fold voltage safety factor in each chamber and a suffi-
iently rapid base rate to assure biventricular pacing for as
uch time as possible.
ollow-up procedures. At a minimum, all ICD patients
ncluded in this study were seen in the clinic and examined
t every three months after implantation. Individual patients
ere also seen and ICD interrogation undertaken at inter-
ening times as circumstances dictated. At each visit, clinical
tatus was documented, pharmacological therapy was re-
orded, and the ICD was interrogated. All ICD generators
ermitted full disclosure of arrhythmia recurrence date, dura-
Abbreviations and Acronyms
ATP  antitachycardia pacing
CARE-HF  Cardiac Resynchronization Heart
Failure trial
COMPANION  Comparison of Medical Therapy,
Pacing, and Defibrillation in Heart
Failure trial
CRT  cardiac resynchronization therapy
HF  heart failure
ICD  implantable cardioverter-defibrillator
LVEF  left ventricular ejection fraction
MIRACLE  Multicenter InSync Randomized
Clinical Evaluation trial
NYHA  New York Heart Association
VF  ventricular fibrillation
VT  ventricular tachycardiaion, and cycle length, as well as the nature and effectiveness of melivered therapies. As appropriate, intracardiac electro-
rams were reviewed, and to the extent possible, the
ppropriateness of ICD shocks and/or antitachycardia pac-
ng (ATP) applications were determined.
None of the patients included in this study were deemed
pacemaker-dependent.” Thus, before initiation of CRT
herapy, none of the patients were exposed to prolonged
eriods of right ventricular apex pacing. The percent of
ardiac cycles that were ventricular paced based on findings
btained at the most recent device interrogation before
upgrade” ranged from 0% to 15%. Subsequent to initiation
f CRT, device follow-up confirmed biventricular pacing
85% (range 85% to 100%) of the time in all cases.
owever, technological limitations preclude being able to
onfirm that biventricular capture was consistently achieved
t all points in time.
efinitions. ARRHYTHMIA BURDEN. The total number of
pisodes and total duration of an arrhythmia in a given time
rame, presented on a per month basis.
ENTRICULAR TACHYCARDIA (VT). Ventricular tachyar-
hythmia with cycle length 400 ms but 320 ms leading
o ICD therapy.
ENTRICULAR FIBRILLATION (VF). Ventricular tachyarrhyth-
able 1. Clinical and Demographic Features
umber of patients 18
ollow-up duration (months)
Prior (range) 47  21 (24–70)
Post (range) 14  12 (9–18)
ge (yrs) 69  11
ender
Male 15 (83%)
Female 3 (17%)
resenting arrhythmia
NSVT 17%
VT 55%
VF 28%
VEF at upgrade (%) 21  8
YHA functional class at upgrade
II 1
III 13
IV 4
YHA functional class at last follow-up
II 6
III 11
IV 1
nderlying disease
Ischemic (%) 11 (61%)
Nonischemic (%) 7 (39%)
edications
Amiodarone (typical long-term dosing:
200 mg once daily)
7 (39%)
Beta-blockers (typical dosing:
metoprolol 50 mg twice daily, or
100 mg long-acting once daily)
8 (44%)
ACE inhibitors 14 (77%)
CE  angiotensin-converting enzyme; LVEF  left ventricular ejection fraction;
SVT  nonsustained ventricular tachycardia; NYHA  New York Heart Associ-
tion; VF  ventricular fibrillation; VT  ventricular tachycardia.ia with cycle length 320 ms leading to ICD therapy.
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Impact of CRT on Ventricular Arrhythmias December 20, 2005:2258–63tatistical analysis. Comparison of arrhythmia frequency
nd characteristics before and after initiation of CRT
herapy utilized the two-tail paired t test. A p value of
0.05 was considered statistically significant.
ESULTS
ighteen patients (15 men, 3 women, mean age was 69 
1 years) received an upgrade to CRT-ICD from a pre-
xisting conventional ICD system. In each case, the indi-
ation for upgrade was to facilitate HF therapy in individ-
als thought to have been already administered maximum
olerable pharmacological treatment. The mean ejection
raction at time of upgrade was 21  8%. Clinical and
emographic features including mean age, male-to-female
atios, underlying heart disease, LVEF, presenting arrhyth-
ia and symptom, NYHA functional class, and medications
re provided in Table 1. Ischemic heart disease comprised
1% of the population. Medications and dosing remained
nchanged after CRT upgrade, except for one patient in
hom amiodarone therapy was terminated due to cutaneous
ide effects.
Patients had been followed for 47 21 months (range 24
o 70 months) before CRT upgrade, and were thereafter
ollowed prospectively for an additional 14  2 months
range 9 to 18 months). Presenting arrhythmias were VT in
5%, VF in 28%, and nonsustained VT in 17%. During the
aseline period, 13 of 18 (72%) patients had at least one VT
nd/or VF event. After CRT-ICD placement, only 2 of 18
11%) had tachyarrhythmic events. The total number of
vents before upgrade was 32  80.5 compared with 0.7 
.2 after the upgrade (p  0.01). Findings were essentially
Table 2. Individual Event Rates (Event/Month
Patients Pre- and Post-CRT Implantation
VT VF
Patient # Pre Post Pre Post
1 0 0 0.27 0
2 0.08 0 0.07 0
3 0 0 0.14 0
4 0.54 0 0 0
5 0.06 0 0.2 0
6 0 0 0.02 0
7 0 0 0 0
8 0 0 0 0
9 33 0 0.4 0.5
10 0 0 0 0
11 0.05 0 0 0
12 0.06 0 0 0
13 0 0 0 0
14 0.01 0 0.07 0
15 0.14 0 0.03 0
16 6.27 0 0 0
17 0.02 0 0 0
18 0 0.19 0 0.09
ATP  antitachycardia pacing; CRT  cardiac resynchron
tachycardia.nchanged when re-examined using comparable durations ff pre- and post-CRT-ICD follow-up in each patient. No
tatistically significant correlation between event rate and
hange in LVEF was detected.
Before CRT the frequency of VT and VF was 0.31 
.23 and 0.047  0.083 episodes per patient per month,
espectively (Table 2). After CRT the frequency of VT and
F was 0.13  0.56 and 0.001  0.004 per patient per
onth, respectively (p  0.01) (Table 2). The decrease in
vent rates after CRT for VT and VF was 0.18 (p  0.59)
nd 0.046 (p  0.03) episodes per patient per month,
espectively.
The frequency of both appropriate ATP applications and
CD shocks was also reduced after CRT upgrade (Table 2).
uring conventional ICD treatment, ATP was applied in
0 of 18 (56%) patients compared with 1 of 18 (3%) after
RT-ICD placement. Similarly, the number of patients
eceiving ICD shocks diminished after CRT. The frequency
f shocks was 0.048  0.085 episodes/month/patient with
he conventional ICD versus 0.003  0.016 episodes/
onth/patient after CRT-ICD (p  0.05). Among the
tudy patients, only one individual exhibited aggravation of
rrhythmia status after CRT initiation.
There were two deaths recorded during follow-up. One
n-hospital death occurred at 18 months after upgrade to
RT-ICD and was due to progressive intractable HF. This
atient had VT episodes after CRT-ICD, but at a decreased
requency than previously. The second death was unwit-
essed, but occurred in an otherwise apparently stable patient
t approximately 16 months after CRT-ICD upgrade. The
CD was not interrogated. This death was deemed to be a
udden death, and occurred in a patient who had not
xhibited any arrhythmias during the CRT-ICD phase of
d Therapy Episodes (Episode/Month) of
Total ATP Shocks
e Post Pre Post Pre Post
7 0 0.27 0 0 0
5 0 0.08 0 0.08 0
4 0 0 0 0.14 0
4 0 0.22 0 0 0
6 0 5 0 0.37 0
2 0 0.08 0 0 0
0 0 0 0 0
0 0 0 0 0
0.5 32.8 0 0.18 0.35
0 0 0 0 0
5 0 0.05 0 0 0
6 0 0.06 0 0 0
0 0 0 0 0
8 0 0.04 0 0.04 0
7 0 0.11 0 0.06 0
7 0 0.08 0 0.02 0
2 0 0.02 0 0 0
0.28 0 0.21 0 0.05
n therapy; VF  ventricular fibrillation; VT  ventricular) an
Pr
0.2
0.1
0.1
0.5
0.2
0.0
0
0
33.4
0
0.0
0.0
0
0.0
0.1
6.2
0.0
0ollow-up.
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December 20, 2005:2258–63 Impact of CRT on Ventricular ArrhythmiasISCUSSION
his study examined the impact of CRT on ventricular
achyarrhythmia susceptibility in patients with pre-existing
onventional ICDs. In each case, an “upgrade” to CRT-
CD was initiated as part of the HF treatment strategy in
hat individual. Pharmacological therapy of HF was already
eemed to be as effective as possible in each patient, and
as not substantially altered during follow-up. The princi-
al findings were that CRT-ICD was associated with
eduction of both ventricular tachyarrhythmia burden and
umber of appropriate ICD therapies, particularly shocks.
urther, after CRT-ICD placement, the nature of ventric-
lar tachyarrhythmia recurrences was altered. Specifically,
he frequency of those tachycardias having the shortest cycle
engths (i.e., those falling within the “VF zone” as defined
y ICD programming) was the most markedly diminished.
mpact of CRT therapy on ventricular arrhythmias. Re-
ent clinical trials have provided ample evidence supporting
he effectiveness of CRT therapy in the treatment of HF
atients with poor left ventricular systolic function (1–11).
he most important positive findings have been diminished
requency of hospitalization, enhanced exercise capacity,
nd improved quality of life. However, the impact of CRT
n arrhythmia susceptibility and mortality has been less
lear, with multiple studies providing differing outcomes
9,11–15,19,20).
The CONTAK-CD (9) and Multicenter InSync Ran-
omized Clinical Evaluation-ICD (MIRACLE-ICD)
10) trials directly addressed the question of whether
RT-ICD therapy offers additional antiarrhythmic benefit
ot available with conventional ICDs. CONTAK-CD (9)
ompared CRT-ICD therapy to conventional ICD treat-
ent. A parallel two-arm design (i.e., CRT-ICD vs. con-
entional ICD) was employed. Ultimately, 490 HF patients
NYHA functional class II to IV) were enrolled. Apart from
F, these individuals exhibited intraventricular conduction
elays and sufficiently severe ventricular arrhythmias to
arrant ICD therapy. All patients received a CRT-capable
evice; in 245 patients the CRT feature was disabled,
hereas in the remaining patients (n  245) both features
ere enabled. After six months, the frequency of observed
rrhythmias did not differ in the two treatment groups; 15%
f CRT patients received appropriate ICD shocks com-
ared with 16% of no-CRT patients. Further, the distribu-
ion of arrhythmias was not substantially different for CRT-
CD versus no-CRT-ICD (VT: 10% vs. 11%, VF: 3% vs. 2%,
oth VT and VF: 2% vs. 2%). Thus, an antiarrhythmic benefit
or CRT was not demonstrable. Similarly, MIRACLE-
CD (10) enrolled 369 patients (182 randomized to CRT
ff, and 187 to ICD-CRT on) with LVEF 35% and
bnormally prolonged QRS duration (130 ms). All en-
ollees were considered to be NYHA functional class III (n
328) or class IV (n  41) despite best available pharma-
ological treatment. The primary end points were changes
etween baseline and six months in quality of life, functional tlass, and 6-min walk distance. However, survival, incidence
f ventricular arrhythmias, and rates of hospitalization were
lso compared. At six months, there was no evident antiar-
hythmic impact of CRT. In terms of “intention-to-treat”
umbers, 26% of control patients had appropriate ICD
hocks versus 24% in CRT-ICD patients (p  0.76).
imilarly, the frequency of ATP did not differ between the
wo groups (31% of controls vs. 33% of CRT-ICD patients,
 0.89).
The absence of CRT-associated antiarrhythmic benefit in
ONTAK-CD and MIRACLE-ICD trials is in contrast
o our findings. In part, this difference may be due to the
act that the CONTAK-CD and MIRACLE-ICD studies
xamined treatment effect in parallel patient populations
ather than within the same individuals. In this regard,
mportant findings previously reported by Higgins et al. (13)
rom the Ventak-CD trial tend to support this view. The
atter report restricted its observations to two periods of
hree months each in patients subjected to biventricular
CD therapy versus ICD treatment without pacing. Among
2 patients enrolled in the Ventak CHF study, ventricular
achyarrhythmias were recorded in 16% of patients during
he CRT phase versus 34% in the no-CRT portion of the
ollow-up (p  0.035).
With regard to mortality, both the Comparison of Med-
cal Therapy, Pacing, and Defibrillation in Heart Failure
COMPANION) trial (11) and the Cardiac Resynchroni-
ation Heart Failure (CARE-HF) trial (20) were suffi-
iently powered to address this end point. These studies
iffered in that COMPANION combined both CRT and
CD, whereas CARE-HF examined CRT effect alone.
evertheless, both tended to support a mortality benefit;
OMPANION reported a mortality reduction that ap-
roached conventionally accepted statistical significance
11) and CARE-HF (20) reported a clear-cut statistically
ignificant reduction of both the primary combined end
oint (i.e., mortality and major cardiovascular events) as well
s mortality alone (a secondary end point). Over an approx-
mate 29 months of average follow-up, CRT was associated
ith a 20% mortality, compared to 30% mortality in
ontrols (95% confidence interval 0.48 to 0.85, p  0.002).
ntiarrhythmic and proarrhythmic balance in CRT. The
otential for CRT to offer a beneficial antiarrhythmic effect
as anticipated by virtue of a theoretically diminished risk
f myocardial ischemia due to improved cardiac output with
educed wall stress, and a more advantageous neurohumoral
mpact on diseased myocardium (19–22). On the other hand,
he potential for an epicardial pacing-induced proarrhythmic
ffect to occur during CRT by altering the direction and
uration of left ventricular repolarization has raised concern
23). Thus, the possibility exists that the beneficial and
dverse effects of CRT on arrhythmia susceptibility may
end to counteract each other making it difficult to discern
true arrhythmia or mortality benefit. Large study popula-
ions may overcome this difficulty, as suggested by the
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Impact of CRT on Ventricular Arrhythmias December 20, 2005:2258–63emonstration of CRT mortality benefit in a recent meta-
nalysis combining multiple CRT studies (24).
In terms of a possible CRT-triggered proarrhythmic effect,
arly concern arose in the Multisite Stimulation in Cardiomy-
pathy (MUSTIC) trial (4) as a result of deaths that occurred
hortly after cross-over from conventional pacing to biventricu-
ar stimulation. Ultimately, it was concluded that the deaths
ere attributable to specific clinical circumstances in each case.
ore recently, despite improved hemodynamic state in
ARE-HF, the investigators did observe a 7% sudden death
ate in their CRT patients. A similar trend was noted in
OMPANION. However, rather than a proarrhythmic
ffect, it is more likely that CRT, by reducing HF deaths,
ay seem to tip the balance toward sudden deaths. In any
ase, such an outcome further favors the need for CRT-
CD combinations.
tudy limitations. The analysis in this study is subject to
mportant limitations. First, by virtue of the fact that our
atient cohort included only individuals in whom upgrade
o CRT was based on hemodynamic indications, we may
ave selected a relatively sick patient population. Such a
opulation may have had a higher ambient level of cardiac
rrhythmia than would be observed in a more typical group of
RT candidates. If true, one could argue that any CRT-
CD benefit was magnified by the study design, thereby
llowing benefit to be detectable in a relatively small cohort.
n the other hand, even if the benefit were small and only
iscernable in this manner, one would not expect the
irection of this treatment effect to have been altered by
irtue of being studied in a very sick population. A demon-
trable benefit or, at worst, a neutral effect, would be a
easonable expectation in less sick patients. Second, we have
nferred from the findings that the CRT feature was the
rincipal factor reducing arrhythmia susceptibility. How-
ver, CRT therapy is inherently accompanied by “overdrive”
acing in order to maintain control over the ventricular
ctivation sequence. Although unlikely, it is possible that
acing alone could have been primarily responsible for
iminishing arrhythmia susceptibility in our cohort. Third,
he patient population, although consecutive, was not ran-
omized and the pre-upgrade arrhythmia status was deter-
ined retrospectively. While a prospective approach is
enerally conceded to be superior, this aspect of the study
esign eliminated inclusion of patients in whom upgrade to
RT was motivated principally by a desire to try to reduce
rrhythmia burden. Fourth, the study population was small,
nd the two deaths during follow-up might be considered to
epresent a mortality concern. On the other hand, the crude
ortality rate in this study was only approximately 7.4% per
ear, which is reasonable given the nature of the HF
opulation. Fifth, we were unable to demonstrate a corre-
ation between reduction of arrhythmia event rates and positive
hange in LVEF. Conceivably, more sensitive measures of
ltered hemodynamic status, such as changes in circulating
atecholamines or brain natriuretic peptide levels, might be
ore effective in evaluating such a relationship. Finally, themall study population leaves open concern that the de-
ected apparent CRT benefit was overestimated by chance.
onsequently, given this last concern, as well as the previ-
usly stated limitations, the findings reported here must be
nterpreted with caution, and perhaps are best used as the
asis for designing a prospective randomized trial.
onclusions. This study examined ventricular arrhythmia
urden and ICD treatment frequency in patients in whom
F treatment dictated the need for replacing a pre-existing
onventional ICD system with a CRT-ICD. The availability
n each of these individuals of a full-featured ICD, both before
nd after introduction of CRT, along with absence of substan-
ial alterations of drug therapy, permitted detailed assessment
f the impact of CRT on arrhythmia susceptibility in these
atients. The findings suggest that, in the setting of dimin-
shed left ventricular systolic function and HF, CRT does
iminish both tachyarrhythmia susceptibility and the fre-
uency of either ICD shock or ATP. Thus, while potential
ortality benefits cannot be addressed in this study, CRT
ppears to reduce tachyarrhythmia risk and also the need for
CD treatment intervention in these high-risk patients.
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